

Getwell Pharma India Pvt. Ltd.

Corporate office: Emaar Digital Greens, 715,7th Floor, Tower A Golf Course Ext. Road Sector 61, Gurugram 122011 Haryana, India Ph: +91-124-4477981/82 Fax: +91-124-4477986 e-mail : info@getwelloncology.com


www.getwelloncology.com

Manufacturing Facilities Unit-1 474, Udyog Vihar, Phase-V, Gurgaon-122016, Haryana, India

Unit-2 Plot No. 381, Sector 3, Phase IV, HSIIDC, IMT Bawal-123501, Haryana, INDIA



Notes	
	Tab
	Ιαυ
	PRODUCT FOR SO
	PRODUCT FOR HE
	PRODUCTS FOR SU





PRODUCTS FOR HEMATOLOGICAL MALIGNANCIES

Sr. No.	Generic Name	Product Name	Strength	Pack Size
29	Azacitidine for Injection	AZACITE™	100mg	1 Vial
30	Bendamustine Injection	BENDAWEL™	100mg	1 Vial
31	Bleomycin for Injection	BLEOWEL™	15 Units	1 Vial
32	Cytarabine Injection	CYTOWEL™	100mg/ml, 500mg/5ml, 1g/10ml	1 Vial
33	Decitabine Lyophilized Powder for Injection	DECIMA™	50mg	1 Vial
34	Lenalidomide Capsules	LENADO™	5mg, 10mg, 25mg	10 Capsules
35	L-Asparaginase for Injection	L-GINASE [™]	5000 I.U., 10000 I.U.	1 Vial
36	Imatinib Mesylate Tablets	MATNIB™	100mg, 400mg	1 x 10 Tablets
37	Bortezomib Injection	NEOMIB®	2mg, 3.5mg	1 Vial
38	Thalidomide Capsules	THALIMIDE™	50mg, 100mg	3 x 10 Capsules

PRODUCTS FOR SUPPORTIVE CARE

39	Dexamethasone Tablets	DEXAM™	4mg, 8mg	5 x 8 Tablets
40	L-Glutamine Oral Powder	GLUTAM [™] -15	15g	5 Sachets x 15g
41	Leucovorin Calcium Injection	LEUCOWEL™	15mg/2ml, 50mg/5ml	5 Ampoules, 1 Vial
42	Megestrol Acetate Tablets	MEGETRA™	40mg, 160mg	1 X 10 Tablets
43	Zoledronic Acid Injection	ZOLDRON™	4mg	1 Vial

PIPELINE PRODUCTS

	Generic Name	Strength	Pack Size
A	Liposomal Irinotecan Injection	43mg/10ml	1 Vial
В	Asparaginase Erwinia Chrysanthemia for Injection	10000 I.U.	1 Vial
С	Gemcitabine Injection (Ready to Use)	200mg, 1g, 1.4g	1 Vial
D	Pemetrexed Injection (Ready to Use)	100mg, 500mg	1 Vial
E	Cyclophosphamide Injection (Ready to Use)	200mg, 500mg, 1gm	1 Vial
F	Bortezomib Injection (Ready to Use)	1mg, 2mg, 3.5mg	1 Vial
G	Bendamustine Hydrochloride Injection (Ready to Use)	25mg, 100mg	1 Vial

PRODUCT FOR SOLID TUMORS

I-DOX [®] (Doxorubicin Hydrochloride Liposome Injecti As Pegylated Liposome		
STRENGTHS	DESCRIPTION	PACKSIZE
20 mg/10 ml 50 mg/25 ml	Single Dose Vial Single Dose Vial	1 Vial 1 Vial

Store between 2°-8°C (36°-46°F) in a refrigerator. Do not freeze.

Major Indications

- In AIDS related Kaposi Sarcoma

NANOPACTM Paclitaxel (protein-bound particles) for Injectable Suspension

STRENGTH	DESCRIPTION	PACK SIZE
100 mg	Single Dose Vial	1 Vial

Store below 25°C (77°F). Protect from light.

Major Indications

- Metastatic Breast Cancer (MBC)
- Non Small Cell Lung Cancer (NSCLC)
- Metastatic Adenocarcinoma of the Pancreas

One Vial Formulation		
STRENGTHS	DESCRIPTION	PACK SIZE
20 mg/ml 80 mg/4 ml 120 mg/6 ml	Single Dose Vial Single Dose Vial Single Dose Vial	1 Vial 1 Vial 1 Vial

Store at a temperature not exceeding 25°C (77°F). Protect from light.

Major Indications

- Hormone Refractory Prostate Cancer (HRPC)
 - Locally Advanced Metastatic Breast Cancer (MBC)
 - Non-Small Cell Lung Cancer (NSCLC)
 - Gastric Adenocarcinoma
 - Head and Neck Cancer

• Metastatic Carcinoma of the Ovary whose disease has progressed or recurred after platinum-based chemotherapy

• Metastatic Breast Cancer patients with increased cardiac risk

• In combination with Bortezomib for patients with Multiple Myeloma

TAXEWELL-RTU[™] (Docetaxel Ready To Use Injection)







TAXEWELL[®] (Docetaxel Injection Concentrate with Solvent)

STRENGTHS	DESCRIPTION	PACKSIZE
20 mg/0.5 ml 80 mg/2 ml 120 mg/3 ml	Single use vial Single use vial Single use vial	1 Vial + Solvent in a combipack

Store under refrigeration between 2°-8° C (36°-46° F). Protect from light.

Major Indications

- Hormone Refractory Prostate Cancer (HRPC)
- Locally Advanced Metastatic Breast Cancer (MBC)
- Non-Small Cell Lung Cancer (NSCLC)
- Gastric Adenocarcinoma
- Head and Neck Cancer



ntrate IP

TAXEWELL

For I.V infusion only SINGLE DOSE VIAL

TAXEWEL

For I.V infusion only

SINGLE DOSE VIAL

GETWELL

PACLIWEL[®] (PaclitaxelInjection)

STRENGTHS	DESCRIPTION	PACKSIZE
30 mg/5 ml	Single Dose Vial	1 Vial 1 Vial
100 mg/16.7 ml 260 mg/43.4 ml	Single Dose Vial Single Dose Vial	1 Vial
300 mg/50 ml	Multi Dose Vial	1 Vial

Store between 20°-25 °C (68°-77 °F). Protect from light. Retain in carton until use.

Major Indications

- Advanced Carcinoma of the Ovary
- Adjuvant treatment of Node- Positive Breast Cancer
- Metastatic Breast Cancer after failure of Combination Chemotherapy
- Non Small Cell Lung Cancer (NSCLC)
- AIDS related Kaposi's Sarcoma

VESTRANTTM (Fulvestrant Injection)

STRENGTH	DESCRIPTION	PACKSIZE
250 mg/5 ml	Single Dose Vial	1 Vial

Store in a refrigerator at 2°-8° C (36°-46° F). Protect from light

Major Indications

- HR-positive advanced Breast Cancer in postmenopausal women with disease progression following endocrine therapy
- Estrogen receptor positive, locally advanced or metastatic Breast Cancer in postmenopausal women not previously treated with endocrine therapy

2



PRODUCT LIST

Sr. No.	Generic Name	Product Name	Strength	Pack Size
1	Capecitabine Tablets	CABITA™	500mg	1 x 10 Tablets
2	Carboplatin Injection	CARBOWEL [™]	150mg/15ml, 450mg/45ml	1 Vial
3	Cisplatin Injection	CISWEL®	10mg/10ml, 50mg/50ml	1 Vial
4	Cyclophosphamide Injection	CYPHOS™	200mg, 500mg, 1g	1 Vial
5	Dacarbazine Injection	DACARB™	200mg, 500mg	1 Vial
6	Doxorubicin Hydrochloride Injection	DOXORUBA™	10mg/5ml, 50mg/25ml	1 Vial
7	Doxorubicin Injection (Lyophilized)	DOXORUBA™	10mg, 50mg	1 Vial
8	Enzalutamide Capsules	ENZAWEL™	40mg	2 x 14 Capsules
9	Epirubicin Hydrochloride for Injection	EPIRUBA™	10mg, 50mg	1 Vial
10	Etoposide Capsules	ETOPA™	50mg, 100mg	1 x 8 Capsules
11	Etoposide Injection	ETOPA™	100mg/5ml	1 Vial
12	Ifosfamide for Injection with Mesna Injection	FOSFA™	1g, 2g, 3g	1 Vial
13	Gemcitabine for Injection	GEMWEL [™]	200mg, 1g, 1.4g	1 Vial
14	Doxorubicin Hydrochloride Liposome Injection (As Pegylated Liposome)	I-DOX [®]	20mg/10ml, 50mg/25ml	1 Vial
15	Methotrexate Injection	METHOTEX™	500mg/20ml, 1g/40ml	1 Vial
16	Paclitaxel (protein-bound particles) for Injectable Suspension	NANOPAC™	100mg	1 Vial
17	Paclitaxel Injection	PACLIWEL®	30mg/5ml, 100mg/16.7ml, 260mg/43.4ml, 300mg/50ml	1 Vial
18	Pemetrexed Injection	PEMETRA [™]	100mg, 500mg	1 Vial
19	Fluorouracil Injection	RACIWEL [™]	250mg/5ml, 500mg/10ml, 1g/20ml	5 Ampoules, 1 Vial
20	Irinotecan Hydrochloride Injection	RINOWEL®	40mg/2ml, 100mg/5ml	1 Vial
21	Docetaxel Injection Concentrate with Solvent	TAXEWELL®	20mg/0.5ml, 80mg/2ml, 120mg/3ml	1 Vial + Solvent in a combipac
22	Docetaxel Injection (One Vial Formulation)	TAXEWELL-RTU [™]	20mg/ml ,80mg/4ml, 120mg/6ml	1 Vial
23	Temozolomide Capsules	TEMZOL [™]	20mg, 100mg, 250mg	1 x 5 Capsules
24	Temozolomide Lyophilized Powder for Injection	TEMZOL™	100mg	1 Vial
25	Thiotepa Injection	TEPAWEL™	15mg, 100mg	1 Vial
26	Dactinomycin for Injection	TINOWEL™	0.5mg	1 Vial
27	Fulvestrant Injection	VESTRANT™	250mg/5ml	1 Vial
28	Oxaliplatin Injection	XYLOTIN [™]	50mg/25ml, 100mg/50ml	1 Vial



PRODUCTS FOR SUPPORTIVE CARE

ULACTA[™] (Urea & Lactic Acid Cream)

Compositi	on	DESCRIPTION	PACKSIZE
Urea Lactic acid Excipients	12.0% w/w 6.0% w/w q.s.	White coloured cream in a round shaped jar	100 g

Store below 25°C (77°F). Protect from light.

Major Indications

- For treating Hand and Foot Syndrome caused by various anti-cancer drugs
- Used for correction of Hyperkeratosis and Dryness in Ichthyosis and allied conditions characterized by dry, rough and scaly skin



GLUTAM[™]-15 (L-Glutamine Oral Powder)

Composition		DESCRIPTION	PACK SIZE
Composition		DESCRIPTION	FACK SIZE
L-Glutamine Orange Flavou	10 g r	Fine graded Powder	5 Sachets x15 g
Excipients	q.s.		

Store below 25°C (77°F). Protect from light and moisture.

Major Indications

• Decreases the incidence and severity of adverse effects due to radiation and chemotherapy in cancer patients such as: Dermatitis, Stomatitis, Oesophagitis, Intestinal Permeability and Diarrhea



DEXAMTM (Dexamethasone Tablets)

l.						
	STRENGTHS	DESCRIPTION	PA	CK S	IZE	
	4 mg 8 mg	Round white biconvex uncoated tablets Round white biconvex uncoated tablets		8 Tabl 8 Tabl		
	Store below 25°C (77°F). Protect from light and moisture.		* Dexan	nethasone DEXAM	
	Major Indicat	ions			5 x 8 Tabl	its ILL
		anagement of Leukemias and Lymphomas cute Leukemias of childhood				
		on in chemotherapy associated nausea nd taxane therapy		CARL C MANA	^R Dexame	thasone



PRODUCT FOR SOLID TUMORS


PEMETRA		
	(Pemetrexed for Injection)	
STRENGTHS	DESCRIPTION	PACKSIZE
100 mg 500 mg	Single Dose Vial Single Dose Vial	1 Vial 1 Vial
from 15-30° C (59° Major Indicati	ons vanced or Metastatic Non Small	ıted
GEMWEL	(Gemcitabine for Injection)	
STDENGTHS		DACKSIZE
STRENGTHS 200 mg	DESCRIPTION Single Dose Vial	PACK SIZE 1 Vial

PEMETRA™ (Pemetrexed for Injection)	
STRENGTHS	DESCRIPTION	PACKSIZE
100 mg 500 mg	Single Dose Vial Single Dose Vial	1 Vial 1 Vial
from 15-30° C (59°- 8 Major Indicatio	nced or Metastatic Non Small	itted
	Gemcitabine for Injection)	
STRENGTHS	DESCRIPTION	PACK SIZE
200 mg 1 g 1.4 g	Single Dose Vial Single Dose Vial Single Dose Vial	1 Vial 1 Vial 1 Vial
Store between 20°-25 from 15-30°C (59°-8 Major Indicatio		itted
•	nced Ovarian Cancer in combinat	tion with Carboplatin prior Anthracycline

CISWEL[®] (Cisplatin Injection)

CTDENICTUS	
STRENGTHS	DE
10 mg/10 ml	Sin
50 mg/50 ml	Sin

Major Indications



PEMETR/

XYLOTIN[™] (Oxaliplatin Injection)

STRENGTHS	DESCRIPTION	PACK SIZE
50 mg/25 ml	Single Dose Vial	1 Vial
100 mg/50 ml	Single Dose Vial	1 Vial

Store between 20°-25°C (68°-77 °F). Protect from light. Retain in carton until use.

Major Indications

- Adjuvant treatment of stage III (Dukes' C) Colon Cancer in patients who have undergone complete resection of the primary tumor
- Advanced Metastatic Colorectal Cancer

0			
	PEX. Jacon Jacon Jacon		
	la l	uvarihiatri infection	Receipt Class for Decision Transmission National Rection Rection Rection Rection
For LV infusion after dilution	A LT P A LT P	Strike Sorse VML For LY Interements	Fox 2nd MAXY No Property Construction Acres For Alter (Syst) Compare - 22 Elementation Compare - 22
		GETWELL	departa
	aliplatin Injection XYLLOTIN 100 mg SNGLE DOSE VAL For LV infusion after dilution	aliplatin Injection	aliplatin Injection

ZOLDRON

STRENGTH	DESCRIPTION	P/
4 mg	Single Dose Vial	

Store between 20°-25°C (68°-77°F). Protect from light.

(Zoledr

Major Indications

- In Hypercalcemia of Malignancy

LEUCOWELTM (Leuco

STRENGTHS	DESCRIPTION	PACKSIZE
15 mg/2 ml	Single Dose Ampoule	5 Ampoules
50 mg/5ml	Single Dose Vial	1 Vial

Store between 2°-8°C (36°-46°F). Do not freeze. Protect from light.

Major Indications

- the toxicity caused by Methotrexate
- For treatment of Megaloblastic Anemia due to folic acid deficiency

MEGETRA[™] (Megestrol Acetate Tablets)

STRENGTHS	DESCRIPTION	PACKSIZE
40 mg 160 mg	White coloured, round, flat uncoated tablets White coloured, round, flat uncoated tablets	1 X 10 Tablets 1 X 10 Tablets
Store below 25°	C (77°F). Protect from light and moisture.	
Breast or End	treatment of Advanced Carcinoma of	ially
	ancer associated Anorexia and Cachexia	
	1	

CARBOWELTM	(Carboplatin Injection)	
STRENGTHS	DESCRIPTION	PACKSIZE
150 mg/15 ml 450 mg/45 ml	Single Dose Vial Single Dose Vial	1 Vial 1 Vial

Store between 20°-25 °C (68°-77 °F). Protect from light. Do not freeze.

Major Indications

- For Ovarian Carcinoma in combination with Cyclophosphamide
- For the palliative treatment of patients with recurrent Ovarian Carcinoma

TEPAWEL[™] (Thiotepa Injection)

STRENGTH	DESCRIPTION	PACKSIZE
100 mg	Single Dose Vial	1 Vial
1 <i>5</i> mg	Single Dose Vial	1 Vial

Store at a temperature of 2-8°C. Protect from light. Do not freeze.

Major Indications

Thiotepa is indicated, in combination with other chemotherapy medicinal products:-

- With or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients
- For the treatment of solid tumors in adults & paediatric patients with high dose chemotherapy during HPCT support
- Malignant Effusions: Thiotepa is indicated for controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities
- Superficial Papillary Carcinoma of the Urinary Bladder





PRODUCTS FOR SUPPORTIVE CARE

onic A	cid to	or Ini	ectio	on)
			0011	

• For Bone Metastasis in patients with Multiple Myeloma and Solid Tumor

ACK SIZE

1 Vial



		\sim			ection	
VO	rin	(al	CIUM	Ini	ection	
		Cur	CI O III		0011011	

• After high dose Methotrexate therapy in Osteosarcoma to diminish

• For use in combination with 5- Fluorouracil to prolong survival in the palliative treatment patients with Advanced Colorectal Cancer



PRODUCT FOR HEMATOLOGICAL MALIGNANCIES

L-GINASE[™] (L-Asparaginase for Injection)

STRENGTHS	DESCRIPTION	PACKSIZE
5000 I.U.	Single Dose Vial	1 Vial
10000 I.U.	Single Dose Vial	1 Vial

Store between 2°-8°C (36°-46°F). Discard reconstituted solution within 8 hours.

Major Indications

• As a component of a multi-agent chemotherapeutic regimen for the treatment of patients with Acute Lymphoblastic Leukemia (ALL)

Asparaginase for lection paraginase for Injection L-GINASE L-GINASE For I.M./I.V. use only GETWELL For I.M./I.V. use only GETWELL

1000010

STRENGTHS	DESCRIPTION	PACK SIZE
15 Units	Single Dose Vial	1 Vial

Store under refrigeration between 2°-8°C (36°-46°F).

BLEOWELTM (Bleomycin for Injection)

Major Indications

- Squamous Cell Carcinoma
- Hodgkin's and Non- Hodgkin's Lymphoma
- Testicular Carcinoma
- Malignant Pleural Effusion

CYTOWEL[™] (CytarabineInjection)

STRENGTHS	DESCRIPTION	PACK SIZE
100 mg/ml	Single Dose Vial	1 Vial
500 mg/5 ml	Single Dose Vial	1 Vial
1 g/10 ml	Single Dose Vial	1 Vial

Store below 25°C (77°F). Protect from light.

Major Indications

• Indicated alone or in combination for induction of remission and/or maintenance in patients with Acute Myeloid Leukaemia, Acute Non Lymphoblastic Leukaemias, Acute Lymphoblastic Leukaemias, Acute Lymphocytic Leukaemia, Erythro Leukaemia, blast crisis of Chronic Myeloid Leukaemia, diffuse Histiocytic Lymphomas (Non-Hodgkin's Lymphomas of high malignancy), Meningeal Leukaemia and Meningeal Neoplasms

12



ENZAWEL[™] (Enzalutamide Capsules)

STRENGTH	DESCRIPTION
40 mg	Hard Gelatin Capsules

Store between 25 °C. Protect from direct sunlight & moisture

Major Indications

- Metastatic & Non Metastatic • Metastatic Castration – Resis
- whose disease has progresse Docetaxel Therapy

TEMZOL[™] (Temozolomide Capsules)

STRENGTHS	DESCRIPTION	PACKSIZE	
20 mg 100 mg	Yellow coloured hard gelatin capsules Sky Blue coloured hard gelatin capsules	1x5 Capsules 1x5 Capsules	
250 mg	White coloured hard gelatin capsules	1x5 Capsules	
Store between 20°	-25°C (68°-77°F). Protect from light and	moisture.	
Major Indicat	ions		Tenozolomide Capsules IP 250 mg
with radiother	osed Glioblastoma Multiforme (GBM) co apy and then as a maintenance treatmen naplastic Astrocytomas		TEMZOL ² 250 solomide (apsules P100 mg TEMZOL ² 100 scenuts GETWELL
	Temozolomide for Injection)	DACKSIZE	
STRENGTHS	DESCRIPTION	PACK SIZE	
		PACK SIZE 1 Vial	
STRENGTHS 100 mg	DESCRIPTION	1 Vial	
STRENGTHS 100 mg	DESCRIPTION Single Dose Vial ration between 2°-8°C (36°-46°F). Do no	1 Vial	Temozotomide Lyophilad

STRENGTHS	DESCRIPTION	PACK SIZE
100 mg	Single Dose Vial	1 Vial



PRODUCT FOR SOLID TUMORS

PACKSIZE 2 x14 Capsules

	3	R Enzalutamide Capsules 40 mg	40 mg	<u></u>
c Prostate Cancer istant Prostate Cancer sed on or after		ENZAWEL [™] 40 एन्ज़ावेल-40 2 x 14 Capovies GETWELL		
		GETWELL		

-

RINOWEL[®] (Irinotecan Hydrochloride Injection)

STRENGTHS	DESCRIPTION	PACKSIZE
40 mg/2 ml	Single Dose Vial	1 Vial
100 mg/5 ml	Single Dose Vial	1 Vial

Store between 20°-25°C (68°-77 °F). Protect from light. Retain in carton until use.

Major Indications

• In Metastatic Carcinoma of Colon & Rectum with 5-Fluorouracil and Leucovorin



RACIWELTM (Fluorouracil Injection)

STRENGTHS	DESCRIPTION	PACK SIZE
250 mg/5 ml	Single Dose Ampoule	5 Ampoule
500 mg/10 ml	Single Dose Ampoule	5 Ampoule
1 gm/20 ml	Single Dose Vial	1 Vial

Store between 20-25°C (68-77°F). Protect from light and retain in the original carton until time of use.

Major Indications

• Effective in the palliative management of Carcinoma of the Colon, Rectum, Breast, Stomach and Pancreas



EPIRUBATM (Epirubicin Hydrochloride for Injection)

STRENGTHS	DESCRIPTION	PACK SIZE
10 mg	Single Dose Vial	1 Vial
50 mg	Single Dose Vial	1 Vial

Store at controlled room temperature 15°-30 °C (59°-86°F). Protect from light.

Major Indications

- Treatment of Neoplastic conditions including :-
- ➤ Carcinoma of the Breast.
- Advanced Ovarian Cancer
- Gastric Cancer
- Small Cell Lung Cancer



PRODUCT FOR HEMATOLOGICAL MALIGNANCIES

LENADOTM (Lenalidomide Capsules) SCRIPTION PACKSIZE hard gelatin capsules 10 Capsules ploured hard gelatin capsules 10 Capsules LENADO-2 ard gelatin capsules 10 Capsules For Oral Use Or 10 Capsules Store below 30°C. Protected from light and moisture. 5 mg Major Indications LENADO-5 10 Capsules For Oral Use Only • Multiple Myeloma in combination with Dexamethasone • Myelodysplastic Syndromes BENDAWELTM (Bendamustine Hydrochloride for Injection) SCRIPTION PACKSIZE ngle Dose Vial 1 Vial Stored between 20°-25°C (68°-77°F); Excursions permitted from 15-30°C (59-86°F). Protect from light. **Major Indications** • In Chronic Lymphocytic Leukemia BENDAWEL • In indolent B-cell Non- Hodgkin's Lymphoma that has progressed during or within six months of treatment with Rituximab SINGLE DOSE VIAL • Multiple Myeloma in combination with prednisone for patient above 65 years non eligible for Autologous Stem Cell Transplantation MATNIBTM (Imatinib Mesylate Tablets) SCRIPTION PACKSIZE capsule shape film coated tablets 1x10 Tablets psule shape film coated tablets 1x10 Tablets / 30°C (86°F). Protect from light and moisture. Major Indications • Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia Philadelphia Positive Chronic Myeloid Leukemia in Blast Crisis, Accelerated MATNIB-400 Phase or Chronic Phase after Interferon-alpha Therapy GETWEL • Adult patients with Philadelphia Positive Acute Lymphoblastic Leukemia • Pediatric patients with Philadelphia Positive Acute Lymphoblastic Leukemia • Myelodysplastic/Myeloproliferative Diseases Aggressive Systemic Mastocytosis atinib Mesylate Tablets 10 • Hypereosinophilic Syndrome and/or Chronic Eosinophilic Leukemia MATNIB-100 • Dermatofibrosarcoma Protuberans G Kit (CD117) positive Gastrointestinal Stromal Tumors Adjuvant Treatment of GIST

STRENGTHS	DE
5 mg 10 mg 25 mg	White coloured Green/Yellow co Blue coloured ha

STRENGTH	DE
100 mg	Sin

STRENGTHS	DE
100 mg 400 mg	Brick Red coloured, Beige coloured, cap
Store below 30	°C (86°F). Protec



PRODUCT FOR HEMATOLOGICAL MALIGNANCIES

NEOMIB[®] (Bortezomib for Injection)

STRENGTHS	DESCRIPTION	PACKSIZE
2 mg	Single Dose Vial	1 Vial
3.5 mg	Single Dose Vial	1 Vial

Store between 20°-25°C (68°-77°F). Protect from light.

Major Indications

- Multiple Myeloma
- Mantle Cell Lymphoma who have received at least 1 prior therapy



Azacitidine for Injectio **AZACITE**

PRODUCT FOR SOLID TUMORS

DOXORUBA[™] (Doxorubicin HCl Injection)

STRENGTHS	DESCRIPTION	PACKSIZE
10 mg/5 ml	Single Dose Vial	1 Vial
50 mg/25 ml	Single Dose Vial	1 Vial

Store under refrigeration between 2°-8°C (36°-46°F). Protect from light.

Major Indications

- Soft Tissue Sarcoma

AZACITETM (Azacitidine for Injection)

STRENGTH	DESCRIPTION	PACKSIZE
100 mg	Single Dose Vial	1 Vial

Store between 20°-25°C (68°-77°F); Excursion permitted from 15-30°C (59°-86°F).

Major Indications

• Myelodysplastic Syndrome Subtypes: Refractory Anemia (RA) or Refractory Anemia with Ringed Sideroblasts, Refractory Anemia with Excess Blasts (RAEB), Refractory Anemia with Excess Blasts in Transformation (RAEB-T) and Chronic Myelomonocytic Leukemia (CMMoL)



STRENGTH	DESCRIPTION	PACK SIZE
50 mg	Single Dose Vial	1 Vial

Store between 20°-25°C (68°-77°F); Excursion permitted from 15-30°C (59°-86°F).

DECIMATM (Decitabine Powder for Injection)

Major Indications

- For the treatment of patients with Myelodysplastic Syndrome (MDS) including previously treated and untreated, denovo and secondary MDS.
- For the treatment of Acute Myeloid Leukemia (AML)



DOXORUBATM (Doxo

STRENGTHS	DESCRIPTION	PACKSIZE
10 mg	Single Dose Vial	1 Vial
50 mg	Single Dose Vial	1 Vial

Store between 15°-30°C (59°-86°F). Protect from light.

Major Indications

- Soft Tissue Sarcoma

DACARBTM (Dacarbazine Injection)

STRENGTHS	DESCRIPTION	PACK SIZE
200 mg	Single Dose Vial	1 Vial
500 mg	Single Dose Vial	1 Vial

Store protected from light and moisture, at a temperature between 2°-8° C (36°-46° F).

Major Indications

• Treatment of Metastatic Malignant Melanoma used in combination with other effective agents

 Carcinoma of the Breast, Lung, Bladder, Thyroid & Ovarian Cancer • Hodgkin's Lymphoma and Non Hodgkin's Lymphoma



rubicin	Lyophi	ized	Powder	for	Injection	

• Carcinoma of the Breast, Lung, Bladder, Thyroid & Ovarian Cancer • Hodgkin's Lymphoma and Non Hodgkin's Lymphoma



• Indicated for Hodgkin's Disease as a second-line therapy when



METHOTEXTM (MethotrexateInjection)

STRENGTHS	DESCRIPTION	PACKSIZE
500 mg/20 ml	Single Dose Vial	1 Vial
1 g/40 ml	Single Dose Vial	1 Vial

Store at controlled room temperature 20°-25°C (68°-77°F). Protect from light.

Major Indications

- Gestational Choriocarcinoma, Chorioadenoma Destruens and Hydatidiform Mole
- Acute Lymphocytic Leukemia, treatment & prophylaxis of Meningeal Leukemia
- Treatment of Breast Cancer, Epidermoid Cancers of the Head and Neck, Advanced Mycosis Fungoides Lung Cancer, particularly Squamous Cell and Advanced stage Non-Hodgkin's Lymphomas

CABITATM (Capecitabine Tablets)

STRENGTH	DESCRIPTION	PACKSIZE
500 mg	Beige coloured, capsule shaped film coated tablets	1x10 Tablets

Store below 30°C (86°F). Protect from light and moisture.

Major Indications

• Treatment of Metastatic Colorectal Cancer and Metastatic **Breast Cancer**

FOSFATM (Ifosfamide for Injection with Mesna Injection)

STRENGTHS	DESCRIPTION	PACKSIZE
1 g	Single Dose Vial	1 Vial
2 g	Single Dose Vial	1 Vial
3 g	Single Dose Vial	1 Vial

Store below 25 °C (77°F). Avoid extended exposure to temperature above 30 °C (86°F).

Major Indications

- In Ovarian, Breast, Testicular Carcinoma, Hyper Nephrone, Pancreatic Carcinoma and Malignant Lymphoma
- In combination with a prophylactic agent for Hemorrhagic Cystitis , such as Mesna

Mesna Injection

- Strengths 2ml, 4ml (Store in a cool and dark place)
- As a prophylactic agent in reducing the incidence of Ifosfamide induced Hemorrhagic Cystitis





FOSFA

FOSE

FOSFA

PRODUCT FOR SOLID TUMORS

CYPHOSTM (Cyclophosphamide Injection)

STRENGTHS	DESCRIPTION	PACKSIZE
200 mg	Single Dose Vial	1 Vial
500 mg	Single Dose Vial	1 Vial
1 g	Single Dose Vial	1 Vial

Store below 25°C (77°F). Avoid extended exposure to temperature above 30°C (86°F)

Major Indications

- Hodgkin's Lymphoma, Lymphocytic Lymphoma, Mixed Cell type Lymphoma, Histocytic Lymphoma, Burkit's Lymphoma, Malignant Lymphomas
- Multiple Myeloma
- Carcinoma of Breast ٠
- Neuroblastoma
- Retinoblastoma

TINOWELTM (Dactinomycin for Injection)

STRENGTHS	DESCRIPTION	PACK SIZE
0.5mg	Single Dose Vial	1 Vial

Store between 20°-25°C (68°-77°F). Protect from light.

Major indications

- Wilm's tumor, Childhood Rhabdomyosarcoma, Ewing's Sarcoma, Metastatic Non-Seminomatous Testicular Cancer and Gestational Trophoblastic Neoplasia
- For Pallative or Adjunctive treatment of Locally Recurrent or Locoregional Solid Malignancies

ETOPATM (Etoposide Injection)

STRENGTHS	DE
100 mg/5 ml	Sin

Store between 20°-25°C (68°-77°F). Protect from light. Do not freeze.

Major Indications

- Small Cell Lung Cancer
- Bladder Cancer ٠
- Non- Hodgkin's Lymphoma
- Gestational Trophoblastic Tumors
 Paediatric Sarcoma- Ewing's Sarcoma

- Leukaemias
- Mycosis Fungoides
- Adenocarcinoma of the Ovary

lactinomycin for Injection USI TINOWEL Lyophilized For I.V Infusion ool Single Dose Vial GETWELL

СҮРНО

CYPHOS

CYPHO

SCRIPTION PACKSIZE ngle Dose Vial 1 Vial

- Testicular Cancer
- Hodgkin's Lymphoma
- Acute Leukaemia

